Yoshihiro kawaoka, University professor

Hyderabad (Telangana) [India], Apr 4 : Bharat biotech is developing a one drop COVID-19 intranasal vaccine 'CoroFlu' using a proven safety platform.The vaccine, 'CoroFLu' is built on a flu vaccine "backbone", which has already proved to be safe and well tolerant when given to humans, in Phase I and II of the clinical trials.The medicine is being developed by Bharat Biotech is an international collaboration with virologists at the University of Wisconsin-Madison and the vaccine compes FluGenCoroFlu will build on the backbone of FluGen's flu vaccine candidate known as M2SR. It is based on an invention by UW-Madison virologists and FluGen co-founders Yoshihiro Kawaoka and Gabriele Neumann.M2SR is a self-limiting version of the influenza virus that induces an immune response against the flu. Kawaoka's lab will insert gene sequences from SARS-CoV-2, the novel coronavirus that causes the disease COVID-19, into M2SR so that the new vaccine will also induce immunity against the coronavirus.Dr.Raches Ella, Head of Business Development, Bharat Biotech said, "Bharat Biotech will manufacture the vaccine, conduct clinical trials, and prepare to produce almost 300 million doses of vaccine for global distribution. Under the collaboration agreement, FluGen will transfer its existing manufacturing processes to Bharat Biotech to enable the company to scale up production and produce the vaccine for clinical trials,"Raches added, "Bharat Biotech has commercialized 16 vaccines, including a vaccine developed against the H1N1 flu that caused the 2009 pandemic."Refinement of the CoroFlu vaccine concept and testing in laboratory mal models at UW-Madison is expected to take three to six months.Bharat Biotech will then begin production scale-up for safety and efficacy testing in humans. CoroFlu could be in human clinical trials by the fall of 2020.Four Phase I and Phase II clinical trials involving hundreds of subjects have shown the M2SR flu vaccine to be safe and well-tolerated.The safety profile, M2SR's ability to induce a strong immune response, and the ability of influenza viruses to carry sequences of other viruses make M2SR an attractive option for rapidly developing CoroFlu as a safe and effective coronavirus vaccine.( With inputs from ANI )

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Narendra Modi

Lok Sabha Election 2024

Heatwave In India

Mumbai Water Cut

Maharashtra Lok Sabha Election

IPL 2024

Yoshihiro KawaokaFOLLOW

Yoshihiro kawaoka, Latest News

Health :Current anti-COVID pills work well against Omicron, antibody drugs less effective: Study

A new study has found the drugs behind the new pills to treat COVID-19 remain very effective against the Omicron variant of the virus in lab tests. ...

Health :Anti-Covid pills work against Omicron, antibody drugs less effective

New York, Jan 27 The drugs behind the new pills to treat Covid-19 remain very effective against the ... ...

Lifestyle :Study shows cats can transmit coronavirus to each other without showing symptoms

A new laboratory experiment has brought to light that cats can easily become infected with SARS-CoV-2, the virus that causes COVID-19, and may be able to pass the virus to other cats. ...

Health :Cats can transmit COVID-19 to other cats, find researchers

Scientists in the US and Japan have documented new evidence that cats can readily become infected with SARS-CoV-2 virus ... ...

Health :Cats can transmit coronavirus to each other, won't show symptoms: Study

Cats can readily become infected with SARS-CoV-2, the virus that causes COVID-19, and may be able to pass the virus to other cats, according to a new laboratory experiment. ...

National :Bharat Biotech developing 'CoroFlu' intranasal vaccine for Coronavirus

Bharat biotech is developing a one drop COVID-19 intranasal vaccine 'CoroFlu' using a proven safety platform. ...